Association of VEGFR2 gene polymorphisms with the effect of L-dopa and dyskinesia complications.
10.11817/j.issn.1672-7347.2015.11.006
- Author:
Yuanliang YAN
1
;
Long QIAN
1
;
Shu FANG
1
;
Zhicheng GONG
1
Author Information
1. Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Antiparkinson Agents;
pharmacology;
Humans;
Levodopa;
pharmacology;
Parkinson Disease;
drug therapy;
genetics;
Polymorphism, Genetic;
Vascular Endothelial Growth Factor Receptor-2;
genetics
- From:
Journal of Central South University(Medical Sciences)
2015;40(11):1199-1204
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the association of VEGFR2 gene polymorphisms (rs2305948 and rs1870377) with the effect of levodopa (L-dopa) and dyskinesia in Chinese population and to provide theoretical basis for clinical treatment.
METHODS:By using Taqman MGB analysis and gene sequencing, the rs2305948 and rs1870377 polymorphisms of 69 enrolled Parkinson's disease (PD) patients were detected. Among them, 32 cases developed dyskinesia during 5 years and 37 cases did not develop dyskinesia during 8 years (as the control).
RESULTS:There was no significant association between the occurrence of dyskinesia and VEGFR2 polymorphisms at rs2305948 and rs1870377. However, rs1870377 polymorphism of AA showed greater maximum L-dopa dose [(565.00±163.55) mg/d vs (396.88±200.39) mg/d, (300.00±80.18) mg/d, P=0.038] and higher value of Modified Abnormal Involuntary Movement Scale (mAIMS) compared with that with polymorphisms of AT and TT [17.00±5.24 vs 8.94±6.53, 7.86±4.45, P=0.026].
CONCLUSION:VEGFR2 genes polymorphism (rs1870377) is associated with maximum L-dopa dose and mAIMS value in PD patients.
